It depends on the standard you follow. As of September 2026, Royalty Pharma plc (RPRX) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones Islamic, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 31.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.93% / 30% · Interest income / Revenue 0.77% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 31.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.99% / 33% · Receivables / Mkt Cap (36m) 3.55% / 49% · Interest income / Revenue 0.77% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 31.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.99% / 33.33% · Receivables / Mkt Cap (24m) 3.55% / 33.33% · Interest income / Revenue 0.77% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 45.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.34% / 33.33% · Receivables / Avg Assets (4Q) 4.51% / 33.33% · Interest income / Revenue 0.77% / 5% | Fail |
| FTSE | Debt / Total Assets 44.1% / 33.33% · (Cash+ST Inv) / Total Assets 2.80% / 33.33% · (Cash+Recv) / Total Assets 7.80% / 33.33% · Interest income / Revenue 0.77% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Royalty Pharma plc (RPRX) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones Islamic, and fails AAOIFI, MSCI and FTSE.
No. Royalty Pharma plc is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.77% of each dividend: Royalty Pharma plc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Royalty Pharma plc (NASDAQ: RPRX) is a Healthcare company (Medical - Pharmaceuticals) with a market capitalization of $30.5B. The Maz Rating grades it against the other companies in its sector.
Royalty Pharma plc's current Maz Rating and its five factor grades are for members: log in to see them.
At $68.53, Royalty Pharma plc trades at 41.0x trailing earnings, 11.7x sales and 4.5x book value, with an EV/EBITDA of 25.1. Over the last twelve months it generated about $2.6B of revenue and $744M of net income. It runs a gross margin of 89.8%, an operating margin of 57.1% and a net margin of 25.7%. It shows return on equity of 9.9%, return on invested capital of 7.8% and a free cash flow yield of 9.7%. On the balance sheet: a debt-to-equity ratio of 1.26 and a current ratio of 1.29. Over the past 52 weeks the share price ranged from $37.31 to $70.37, with a beta of 0.41.
Royalty Pharma plc pays a dividend yielding 1.37%, with 61% of earnings paid out. Its Maz Dividend Score is 3.97 out of 5, ranked against the other dividend payers in its sector (Safety 2.90, Growth 4.30, Yield 4.17, Consistency 2.05).
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.